Identification of the Prognostic Value of Immune-Related Genes in Esophageal Cancer

Overview

Journal Front Genet

Date 2020 Sep 25

PMID 32973887

Citations 16

Authors

Xiong Guo

Yujun Wang

Han Zhang

Chuan Qin

Anqi Cheng

Jianjun Liu

Xinglong Dai

Ziwei Wang

Affiliations

Soon will be listed here.

Abstract

Esophageal cancer (EC) is a serious malignant tumor, both in terms of mortality and prognosis, and immune-related genes (IRGs) are key contributors to its development. In recent years, immunotherapy for tumors has been widely studied, but a practical prognostic model based on immune-related genes (IRGs) in EC has not been established and reported. This study aimed to develop an immunogenomic risk score for predicting survival outcomes among EC patients. In this study, we downloaded the transcriptome profiling data and matched clinical data of EC patients from The Cancer Genome Atlas (TCGA) database and found 4,094 differentially expressed genes (DEGs) between EC and normal esophageal tissue ( < 0.05 and fold change >2). Then, the intersection of DEGs and the immune genes in the "ImmPort" database resulted in 303 differentially expressed immune-related genes (DEIRGs). Next, through univariate Cox regression analysis of DEIRGs, we obtained 17 immune genes related to prognosis. We detected nine optimal survival-associated IRGs () by using Lasso regression and multivariate Cox regression analyses. Finally, we used those survival-associated IRGs to construct a risk model to predict the prognosis of EC patients. This model could accurately predict overall survival in EC and could be used as a classifier for the evaluation of low-risk and high-risk groups. In conclusion, we identified a practical and robust nine-gene prognostic model based on immune gene dataset. These genes may provide valuable biomarkers and prognostic predictors for EC patients and could be further studied to help understand the mechanism of EC occurrence and development.

Citing Articles

Integrated machine learning developed a prognosis-related gene signature to predict prognosis in oesophageal squamous cell carcinoma.

Tang P, Li B, Zhou Z, Wang H, Ma M, Gong L J Cell Mol Med. 2024; 28(21):e70171.

PMID: 39535375 PMC: 11558266. DOI: 10.1111/jcmm.70171.

Interferon signaling and ferroptosis in tumor immunology and therapy.

Hu W, Zhao Z, Du J, Jiang J, Yang M, Tian M NPJ Precis Oncol. 2024; 8(1):177.

PMID: 39127858 PMC: 11316745. DOI: 10.1038/s41698-024-00668-w.

HOXD9 is a potential prognostic biomarker involved in immune microenvironment of glioma.

Xu S, Xiao H, Song T, Zeng Y, Wei C, Chen T J Cancer Res Clin Oncol. 2023; 149(16):14911-14926.

PMID: 37603105 DOI: 10.1007/s00432-023-05275-z.

A robust immune-related gene pairs signature for predicting the overall survival of esophageal cancer.

Zheng W, Fang G, Huang Q, Shi D, Xie B BMC Genomics. 2023; 24(1):385.

PMID: 37430202 PMC: 10332031. DOI: 10.1186/s12864-023-09496-x.

Establishment and validation of exhausted CD8+ T cell feature as a prognostic model of HCC.

Shi J, Li G, Liu L, Yuan X, Wang Y, Gong M Front Immunol. 2023; 14:1166052.

PMID: 37077914 PMC: 10106715. DOI: 10.3389/fimmu.2023.1166052.

References

Huang T, Fu L . The immune landscape of esophageal cancer. Cancer Commun (Lond). 2019; 39(1):79. PMC: 6878621. DOI: 10.1186/s40880-019-0427-z. View

Lagergren J, Smyth E, Cunningham D, Lagergren P . Oesophageal cancer. Lancet. 2017; 390(10110):2383-2396. DOI: 10.1016/S0140-6736(17)31462-9. View

Liu T, Ortiz J, Taing L, Meyer C, Lee B, Zhang Y . Cistrome: an integrative platform for transcriptional regulation studies. Genome Biol. 2011; 12(8):R83. PMC: 3245621. DOI: 10.1186/gb-2011-12-8-r83. View

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

Wan B, Liu B, Huang Y, Yu G, Lv C . Prognostic value of immune-related genes in clear cell renal cell carcinoma. Aging (Albany NY). 2019; 11(23):11474-11489. PMC: 6932908. DOI: 10.18632/aging.102548. View

Fidler I . The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003; 3(6):453-8. DOI: 10.1038/nrc1098. View

Yan T, Cui H, Zhou Y, Yang B, Kong P, Zhang Y . Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma. Nat Commun. 2019; 10(1):1670. PMC: 6459928. DOI: 10.1038/s41467-019-09255-1. View

Bhattacharya S, Dunn P, Thomas C, Smith B, Schaefer H, Chen J . ImmPort, toward repurposing of open access immunological assay data for translational and clinical research. Sci Data. 2018; 5:180015. PMC: 5827693. DOI: 10.1038/sdata.2018.15. View

Qiu H, Hu X, He C, Yu B, Li Y, Li J . Identification and Validation of an Individualized Prognostic Signature of Bladder Cancer Based on Seven Immune Related Genes. Front Genet. 2020; 11:12. PMC: 7013035. DOI: 10.3389/fgene.2020.00012. View

10.

Cunningham D, Allum W, Stenning S, Thompson J, van de Velde C, Nicolson M . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1):11-20. DOI: 10.1056/NEJMoa055531. View

11.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

12.

Zhang M, Wang X, Chen X, Zhang Q, Hong J . Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma. Front Genet. 2020; 11:363. PMC: 7174786. DOI: 10.3389/fgene.2020.00363. View

13.

Allum W, Stenning S, Bancewicz J, Clark P, Langley R . Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009; 27(30):5062-7. DOI: 10.1200/JCO.2009.22.2083. View

14.

Mei S, Meyer C, Zheng R, Qin Q, Wu Q, Jiang P . Cistrome Cancer: A Web Resource for Integrative Gene Regulation Modeling in Cancer. Cancer Res. 2017; 77(21):e19-e22. PMC: 5826647. DOI: 10.1158/0008-5472.CAN-17-0327. View

15.

Gentles A, Newman A, Liu C, Bratman S, Feng W, Kim D . The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015; 21(8):938-945. PMC: 4852857. DOI: 10.1038/nm.3909. View

16.

Noble F, Lloyd M, Turkington R, Griffiths E, ODonovan M, ONeill J . Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma. Br J Surg. 2017; 104(13):1816-1828. PMC: 5725679. DOI: 10.1002/bjs.10627. View

17.

Tanaka T, Nakamura J, Noshiro H . Promising immunotherapies for esophageal cancer. Expert Opin Biol Ther. 2017; 17(6):723-733. DOI: 10.1080/14712598.2017.1315404. View

18.

He Y, Dang Q, Li J, Zhang Q, Yu X, Xue M . Prediction of hepatocellular carcinoma prognosis based on expression of an immune-related gene set. Aging (Albany NY). 2020; 12(1):965-977. PMC: 6977696. DOI: 10.18632/aging.102669. View

19.

Chen P, Yang Y, Zhang Y, Jiang S, Li X, Wan J . Identification of prognostic immune-related genes in the tumor microenvironment of endometrial cancer. Aging (Albany NY). 2020; 12(4):3371-3387. PMC: 7066904. DOI: 10.18632/aging.102817. View

20.

Zhang B, Zhang Z, Li L, Qin Y, Liu H, Jiang C . TSPAN15 interacts with BTRC to promote oesophageal squamous cell carcinoma metastasis via activating NF-κB signaling. Nat Commun. 2018; 9(1):1423. PMC: 5897412. DOI: 10.1038/s41467-018-03716-9. View